newsfilter
← Latest News
Business Wire·

Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors

Patent protects the use of GLIX1 in cancers where cytidine deaminase (CDA) is not over-expressed — representing more than 90% of all cancer types Hemispherian AS, a biotechnology company pioneering first-in-class